1
|
Urbiola-Salvador V, Lima de Souza S, Macur K, Czaplewska P, Chen Z. Plasma Proteomics Elucidated a Protein Signature in COVID-19 Patients with Comorbidities and Early-Diagnosis Biomarkers. Biomedicines 2024; 12:840. [PMID: 38672194 PMCID: PMC11048573 DOI: 10.3390/biomedicines12040840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2024] [Revised: 04/03/2024] [Accepted: 04/04/2024] [Indexed: 04/28/2024] Open
Abstract
Despite great scientific efforts, deep understanding of coronavirus-19 disease (COVID-19) immunopathology and clinical biomarkers remains a challenge. Pre-existing comorbidities increase the mortality rate and aggravate the exacerbated immune response against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, which can result in more severe symptoms as well as long-COVID and post-COVID complications. In this study, we applied proteomics analysis of plasma samples from 28 patients with SARS-CoV-2, with and without pre-existing comorbidities, as well as their corresponding controls to determine the systemic protein changes caused by the SARS-CoV-2 infection. As a result, the protein signature shared amongst COVID-19 patients with comorbidities was revealed to be characterized by alterations in the coagulation and complement pathways, acute-phase response proteins, tissue damage and remodeling, as well as cholesterol metabolism. These altered proteins may play a relevant role in COVID-19 pathophysiology. Moreover, several novel potential biomarkers for early diagnosis of the SARS-CoV-2 infection were detected, such as increased levels of keratin K22E, extracellular matrix protein-1 (ECM1), and acute-phase response protein α-2-antiplasmin (A2AP). Importantly, elevated A2AP may contribute to persistent clotting complications associated with the long-COVID syndrome in patients with comorbidities. This study provides new insights into COVID-19 pathogenesis and proposes novel potential biomarkers for early diagnosis that could be facilitated for clinical application by further validation studies.
Collapse
Affiliation(s)
- Víctor Urbiola-Salvador
- Intercollegiate Faculty of Biotechnology of University of Gdańsk and Medical University of Gdańsk, University of Gdańsk, 80-307 Gdańsk, Poland;
| | - Suiane Lima de Souza
- Faculty of Biochemistry and Molecular Medicine, University of Oulu, 90220 Oulu, Finland;
| | - Katarzyna Macur
- Laboratory of Mass Spectrometry-Core Facility Laboratories, Intercollegiate Faculty of Biotechnology University of Gdańsk and Medical University of Gdańsk, University of Gdańsk, 80-309 Gdańsk, Poland; (K.M.); (P.C.)
| | - Paulina Czaplewska
- Laboratory of Mass Spectrometry-Core Facility Laboratories, Intercollegiate Faculty of Biotechnology University of Gdańsk and Medical University of Gdańsk, University of Gdańsk, 80-309 Gdańsk, Poland; (K.M.); (P.C.)
| | - Zhi Chen
- Faculty of Biochemistry and Molecular Medicine, University of Oulu, 90220 Oulu, Finland;
| |
Collapse
|
2
|
Pascreau T, Zia-Chahabi S, Vasse M. Letter to the editor regarding "Protein Z and Protein Z-dependent protease inhibitor in patients with acute ischemic stroke: A prospective mechanistic study". J Stroke Cerebrovasc Dis 2024; 33:107480. [PMID: 37953074 DOI: 10.1016/j.jstrokecerebrovasdis.2023.107480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Accepted: 11/07/2023] [Indexed: 11/14/2023] Open
Affiliation(s)
- Tiffany Pascreau
- Biology Department, Foch Hospital, Suresnes & Université Paris-Saclay, INSERM, Hémostase Inflammation Thrombose HITh U1176, 94276, Le Kremlin-Bicêtre, France
| | | | - Marc Vasse
- Biology Department, Foch Hospital, Suresnes & Université Paris-Saclay, INSERM, Hémostase Inflammation Thrombose HITh U1176, 94276, Le Kremlin-Bicêtre, France.
| |
Collapse
|
3
|
Carbonnel M, Daclin C, Tourne M, Roux E, Le-Marchand M, Racowsky C, Kennel T, Farfour E, Vasse M, Ayoubi JM. Impact of COVID-19 on Subclinical Placental Thrombosis and Maternal Thrombotic Factors. J Clin Med 2022; 11:jcm11144067. [PMID: 35887831 PMCID: PMC9323982 DOI: 10.3390/jcm11144067] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Revised: 07/04/2022] [Accepted: 07/09/2022] [Indexed: 02/04/2023] Open
Abstract
Background: In the context of the SARS-CoV-2 pandemic, our interest was to evaluate the effect of COVID-19 during pregnancy on placenta and coagulation factors. Methods: a prospective cohort study between January and July 2021 of 55 pregnant women stratified into: Group O, 16 patients with ongoing SARS-CoV-2 infection at delivery; Group R, 21 patients with a history of SARS-CoV-2 infection during pregnancy but who recovered prior to delivery; Group C, 18 control patients with no infection at any time. All women had nasopharyngeal SARS-CoV-2 RT-PCR tests performed within 72 h of delivery. Obstetrical complications were recorded and two physiological inhibitors of coagulation, protein Z (PZ) and dependent protease inhibitor (ZPI), were analyzed in maternal and cord blood. All placentae were analyzed by a pathologist for vascular malperfusion. Results: No patient in any group had a severe COVID-19 infection. More obstetrical complications were observed in Group O (O: n = 6/16 (37%), R: n = 2/21 (10%), C: n = 1/18 (6%), p = 0.03). The incidence of placental vascular malperfusion was similar among the groups (O: n = 9/16 (56%), R: n = 8/21 (42%), C: n = 8/18 (44%), p = 0.68). No PZ or ZPI deficiency was associated with COVID-19. However, an increased ZPI/PZ ratio was observed in neonates of Group R (O: 82.6 (min 41.3–max 743.6), R: 120.7 (29.8–203.5), C: 66.8 (28.2–2043.5), p = 0.04). Conclusion: COVID-19 was associated with more obstetrical complications, but not an increased incidence of placental lesions or PZ and ZPI abnormalities.
Collapse
Affiliation(s)
- Marie Carbonnel
- Department of Obstetrics and Gynecology, Hospital Foch, 40, Rue Worth, 92150 Suresnes, France; (C.D.); (C.R.); (J.-M.A.)
- Medical School, University of Versailles, Saint-Quentin-en-Yvelines, 55, Avenue de Paris, 78000 Versailles, France;
- Correspondence:
| | - Camille Daclin
- Department of Obstetrics and Gynecology, Hospital Foch, 40, Rue Worth, 92150 Suresnes, France; (C.D.); (C.R.); (J.-M.A.)
| | - Morgan Tourne
- Medical School, University of Versailles, Saint-Quentin-en-Yvelines, 55, Avenue de Paris, 78000 Versailles, France;
- Department of Pathology, Hospital Foch, Hospital Foch, 40, Rue Worth, 92150 Suresnes, France
| | - Emmanuel Roux
- Department of Clinic Research, Hospital Foch, 40, Rue Worth, 92150 Suresnes, France; (E.R.); (M.L.-M.); (T.K.)
| | - Mathilde Le-Marchand
- Department of Clinic Research, Hospital Foch, 40, Rue Worth, 92150 Suresnes, France; (E.R.); (M.L.-M.); (T.K.)
| | - Catherine Racowsky
- Department of Obstetrics and Gynecology, Hospital Foch, 40, Rue Worth, 92150 Suresnes, France; (C.D.); (C.R.); (J.-M.A.)
- Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Boston, MA 02115, USA
| | - Titouan Kennel
- Department of Clinic Research, Hospital Foch, 40, Rue Worth, 92150 Suresnes, France; (E.R.); (M.L.-M.); (T.K.)
| | - Eric Farfour
- Department of Clinical Biology, Hospital Foch, 40, Rue Worth, 92150 Suresnes, France; (E.F.); (M.V.)
| | - Marc Vasse
- Department of Clinical Biology, Hospital Foch, 40, Rue Worth, 92150 Suresnes, France; (E.F.); (M.V.)
- UMR-S 1176, Institut National de la Santé et de la Recherche Médicale, Université Paris-Saclay, 94270 Le Kremlin-Bicêtre, France
| | - Jean-Marc Ayoubi
- Department of Obstetrics and Gynecology, Hospital Foch, 40, Rue Worth, 92150 Suresnes, France; (C.D.); (C.R.); (J.-M.A.)
- Medical School, University of Versailles, Saint-Quentin-en-Yvelines, 55, Avenue de Paris, 78000 Versailles, France;
| |
Collapse
|